KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $131.4 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) rose 222.18% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.4 million, marking a year-over-year increase of 222.18%. This contributed to the annual value of $127.7 million for FY2024, which is 219.77% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) is $131.4 million, which was up 222.18% from $130.6 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $131.4 million during Q3 2025, and registered a low of $117.1 million during Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $124.7 million (recorded in 2023), while the average stood at $124.1 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 384.22% in 2021, then surged by 163.32% in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $118.5 million in 2021, then grew by 2.73% to $121.7 million in 2022, then grew by 2.64% to $124.9 million in 2023, then increased by 2.2% to $127.7 million in 2024, then grew by 2.97% to $131.4 million in 2025.
  • Its last three reported values are $131.4 million in Q3 2025, $130.6 million for Q2 2025, and $129.7 million during Q1 2025.